Fatty Liver Disease

Categories: Cancer diseases, Gastrointestinal diseases, Genetic diseases, Liver diseases, Metabolic diseases
Data Licensing
For inquiries, contact:

Aliases & Classifications for Fatty Liver Disease

MalaCards integrated aliases for Fatty Liver Disease:

Name: Fatty Liver Disease 11 41 14 75
Alcoholic Fatty Liver 11 31 33
Fatty Liver, Alcoholic 43 71
Fatty Liver 43 71
Etoh Fatty Liver Metamorphosis 33
Fatty Etoh Liver Necrosis 33
Fatty Change of Liver 11
Fatty Liver Alcoholic 53
Steatosis of Liver 11
Hepatic Lipidosis 11
Etoh Fatty Liver 33
Steatohepatitis 71


External Ids:

Disease Ontology 11 DOID:9452
ICD9CM 34 571.0
SNOMED-CT 68 371330000 50325005
ICD10 31 K70.0 K76.0
ICD11 33 1759668616
UMLS 71 C0015695 C0015696 C2711227

Summaries for Fatty Liver Disease

MedlinePlus: 41 What is fatty liver disease? Your liver is the largest organ inside your body. It helps your body digest food, store energy, and remove poisons. Fatty liver disease is a condition in which fat builds up in your liver. There are two main types: Nonalcoholic fatty liver disease (NAFLD) Alcoholic fatty liver disease, also called alcoholic steatohepatitis What is nonalcoholic fatty liver disease (NAFLD)? NAFLD is a type of fatty liver disease that is not related to heavy alcohol use. There are two kinds: Simple fatty liver, in which you have fat in your liver but little or no inflammation or liver cell damage. Simple fatty liver typically does not get bad enough to cause liver damage or complications. Nonalcoholic steatohepatitis (NASH), in which you have inflammation and liver cell damage, as well as fat in your liver. Inflammation and liver cell damage can cause fibrosis, or scarring, of the liver. NASH may lead to cirrhosis or liver cancer. What is alcoholic fatty liver disease? Alcoholic fatty liver disease is due to heavy alcohol use. Your liver breaks down most of the alcohol you drink, so it can be removed from your body. But the process of breaking it down can generate harmful substances. These substances can damage liver cells, promote inflammation, and weaken your body's natural defenses. The more alcohol that you drink, the more you damage your liver. Alcoholic fatty liver disease is the earliest stage of alcohol-related liver disease. The next stages are alcoholic hepatitis and cirrhosis. Who is at risk for fatty liver disease? The cause of nonalcoholic fatty liver disease (NAFLD) is unknown. Researchers do know that it is more common in people who: Have type 2 diabetes and prediabetes Have obesity Are middle aged or older (although children can also get it) Are Hispanic, followed by non-Hispanic whites. It is less common in African Americans. Have high levels of fats in the blood, such as cholesterol and triglycerides Have high blood pressure Take certain drugs, such as corticosteroids and some cancer drugs Have certain metabolic disorders, including metabolic syndrome Have rapid weight loss Have certain infections, such as hepatitis C Have been exposed to some toxins NAFLD affects about 25% of people in the world. As the rates of obesity, type 2 diabetes, and high cholesterol are rising in the United States, so is the rate of NAFLD. NAFLD is the most common chronic liver disorder in the United States. Alcoholic fatty liver disease only happens in people who are heavy drinkers, especially those who have been drinking for a long period of time. The risk is higher for heavy drinkers who are women, have obesity, or have certain genetic mutations. What are the symptoms of fatty liver disease? Both NAFLD and alcoholic fatty liver disease are usually silent diseases with few or no symptoms. If you do have symptoms, you may feel tired or have discomfort in the upper right side of your abdomen. How is fatty liver disease diagnosed? Because there are often no symptoms, it is not easy to find fatty liver disease. Your doctor may suspect that you have it if you get abnormal results on liver tests that you had for other reasons. To make a diagnosis, your doctor will use: Your medical history A physical exam Various tests, including blood and imaging tests, and sometimes a biopsy As part of the medical history, your doctor will ask about your alcohol use, to find out whether fat in your liver is a sign of alcoholic fatty liver disease or nonalcoholic fatty liver (NAFLD). He or she will also ask which medicines you take, to try to determine whether a medicine is causing your NAFLD. During the physical exam, your doctor will examine your body and check your weight and height. Your doctor will look for signs of fatty liver disease, such as: An enlarged liver Signs of cirrhosis, such as jaundice, a condition that causes your skin and whites of your eyes to turn yellow You will likely have blood tests, including liver function tests and blood count tests. In some cases you may also have imaging tests, like those that check for fat in the liver and the stiffness of your liver. Liver stiffness can mean fibrosis, which is scarring of the liver. In some cases you may also need a liver biopsy to confirm the diagnosis, and to check how bad the liver damage is. What are the treatments for fatty liver disease? Doctors recommend weight loss for nonalcoholic fatty liver. Weight loss can reduce fat in the liver, inflammation, and fibrosis. If your doctor thinks that a certain medicine is the cause of your NAFLD, you should stop taking that medicine. But check with your doctor before stopping the medicine. You may need to get off the medicine gradually, and you might need to switch to another medicine instead. There are no medicines that have been approved to treat NAFLD. Studies are investigating whether a certain diabetes medicine or Vitamin E can help, but more studies are needed. The most important part of treating alcohol-related fatty liver disease is to stop drinking alcohol. If you need help doing that, you may want to see a therapist or participate in an alcohol recovery program. There are also medicines that can help, either by reducing your cravings or making you feel sick if you drink alcohol. Both alcoholic fatty liver disease and one type of nonalcoholic fatty liver disease (nonalcoholic steatohepatitis) can lead to cirrhosis. Doctors can treat the health problems caused by cirrhosis with medicines, operations, and other medical procedures. If the cirrhosis leads to liver failure, you may need a liver transplant. What are some lifestyle changes that can help with fatty liver disease? If you have any of the types of fatty liver disease, there are some lifestyle changes that can help: Eat a healthy diet, limiting salt and sugar, plus eating lots of fruits, vegetables, and whole grains Get vaccinations for hepatitis A and B, the flu and pneumococcal disease. If you get hepatitis A or B along with fatty liver, it is more likely to lead to liver failure. People with chronic liver disease are more likely to get infections, so the other two vaccinations are also important. Get regular exercise, which can help you lose weight and reduce fat in the liver Talk with your doctor before using dietary supplements, such as vitamins, or any complementary or alternative medicines or medical practices. Some herbal remedies can damage your liver.

MalaCards based summary: Fatty Liver Disease, also known as alcoholic fatty liver, is related to non-alcoholic fatty liver disease and fatty liver disease 1. An important gene associated with Fatty Liver Disease is NAFLD1 (Fatty Liver Disease 1, Susceptiblity To), and among its related pathways/superpathways are Signal Transduction and IL-9 Signaling Pathways. The drugs Tocopherol and Losartan have been mentioned in the context of this disorder. Affiliated tissues include liver, skeletal muscle and kidney, and related phenotypes are Increased shRNA abundance (Z-score > 2) and homeostasis/metabolism

Disease Ontology: 11 A lipid storage disease characterized by the accumulation of large vacuoles of triglyceride fat in liver cells via the process of steatosis.

Wikipedia: 75 Fatty liver disease (FLD), also known as hepatic steatosis, is a condition where excess fat builds up in... more...

Related Diseases for Fatty Liver Disease

Diseases in the Fatty Liver Disease family:

Fatty Liver Disease 1 Fatty Liver Disease 2

Diseases related to Fatty Liver Disease via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 1044)
# Related Disease Score Top Affiliating Genes
1 non-alcoholic fatty liver disease 34.2 TNF SREBF1 PPARA PNPLA3 NR1H4 LEPR
2 fatty liver disease 1 33.8 PNPLA3 NAFLD1
3 liver disease 33.6 XBP1 TNF SREBF1 PPARA PNPLA3 NR1H4
4 alcohol dependence 33.5 TNF PPARA LEP INS CYP2E1
5 non-alcoholic steatohepatitis 33.4 TNF SREBF1 PPARA PNPLA3 NR1H4 LEP
6 abdominal obesity-metabolic syndrome 1 32.8 PPARA NR1H4 LEPR LEP INS ADIPOQ
7 alcohol use disorder 32.8 TNF INS IL6 CYP2E1
8 type 2 diabetes mellitus 32.7 XBP1 TNF SREBF1 PPARA PNPLA3 NR1H4
9 lipid metabolism disorder 32.7 TNF SREBF1 PPARA NR1H4 LEPR LEP
10 hyperlipidemia, familial combined, 3 32.5 PPARA LEPR INS ADIPOQ
11 leptin deficiency or dysfunction 32.5 TNF SREBF1 PPARA LEPR LEP IRS2
12 body mass index quantitative trait locus 11 32.4 TNF SREBF1 PPARA PNPLA3 NR1H4 LEPR
13 prediabetes syndrome 32.3 LEPR LEP IRS1 INS ADIPOQ
14 cardiovascular system disease 32.2 TNF PPARA NR1H4 LEPR LEP INS
15 atherosclerosis susceptibility 32.2 TNF PPARA LEP INS IL6 CCL2
16 liver cirrhosis 32.2 TNF PNPLA3 MALAT1 LEPR LEP INS
17 apnea, obstructive sleep 32.2 TNF LEP INS IL6 ADIPOQ
18 polycystic ovary syndrome 32.1 LEP IRS2 IRS1 INS ADIPOQ
19 sleep apnea 32.1 TNF LEPR LEP INS IL6 CCL2
20 hyperinsulinism 32.1 SREBF1 PPARA LEPR LEP IRS2 IRS1
21 chronic kidney disease 32.1 TNF LEP INS IL6 ADIPOQ
22 glucose intolerance 32.1 TNF LEPR LEP IRS1 INS IL6
23 nutritional deficiency disease 32.0 LEPR LEP IL6 ADIPOQ
24 kidney disease 32.0 TNF LEP INS IL6 CYP2E1 CCL2
25 hepatocellular carcinoma 32.0 XBP1 TNF SREBF1 PPARA MALAT1 LEPR
26 familial hyperlipidemia 31.9 PPARA LEP INS ADIPOQ
27 diabetes mellitus 31.9 XBP1 TNF SREBF1 PPARA PNPLA3 NR1H4
28 arteries, anomalies of 31.9 TNF INS IL6 CCL2 ADIPOQ
29 lipoprotein quantitative trait locus 31.9 TNF PPARA IRS1 INS IL6 CCL2
30 adult syndrome 31.8 TNF PPARA LEP INS IL6 ADIPOQ
31 type 1 diabetes mellitus 31.7 TNF LEPR LEP INS IL6
32 hyperglycemia 31.7 TNF MALAT1 LEP IRS2 IRS1 INS
33 inflammatory bowel disease 31.7 XBP1 TNF PPARA NR1H4 LEP IRS2
34 hypertension, essential 31.7 TNF SREBF1 PPARA LEPR LEP IRS1
35 vascular disease 31.7 TNF NR1H4 LEP INS IL6 CCL2
36 gestational diabetes 31.7 TNF LEPR LEP IRS2 IRS1 INS
37 bowel dysfunction 31.7 TNF INS IL6
38 overnutrition 31.7 TNF SREBF1 PPARA LEPR LEP IRS1
39 alcoholic hepatitis 31.6 TNF IL6 CYP2E1 CCL2
40 severe covid-19 31.6 TNF IL6 CCL2
41 disseminated intravascular coagulation 31.6 TNF IL6 CCL2
42 primary biliary cholangitis 31.5 TNF PPARA PNPLA3 NR1H4 INS IL6
43 alcoholic liver cirrhosis 31.5 TNF INS IL6 CYP2E1
44 celiac disease 1 31.5 TNF LEP INS IL6 CCL2
45 varicose veins 31.5 TNF IL6 CCL2
46 proteasome-associated autoinflammatory syndrome 1 31.5 TNF PPARA INS IL6 CCL2 ADIPOQ
47 choline deficiency disease 31.5 SREBF1 PPARA NR1H4 INS
48 gastroesophageal reflux 31.5 TNF IL6 CCL2 ADIPOQ
49 cholelithiasis 31.4 NR1H4 LEP INS
50 conn's syndrome 31.4 TNF LEP INS IL6 ADIPOQ

Comorbidity relations with Fatty Liver Disease via Phenotypic Disease Network (PDN):

Alcohol Use Disorder Alcoholic Hepatitis
Alcoholic Liver Cirrhosis

Graphical network of the top 20 diseases related to Fatty Liver Disease:

Diseases related to Fatty Liver Disease

Symptoms & Phenotypes for Fatty Liver Disease

GenomeRNAi Phenotypes related to Fatty Liver Disease according to GeneCards Suite gene sharing:

25 (show all 15)
# Description GenomeRNAi Source Accession Score Top Affiliating Genes
1 Increased shRNA abundance (Z-score > 2) GR00366-A-104 9.53 LEP
2 Increased shRNA abundance (Z-score > 2) GR00366-A-110 9.53 IRS2
3 Increased shRNA abundance (Z-score > 2) GR00366-A-111 9.53 IRS2
4 Increased shRNA abundance (Z-score > 2) GR00366-A-112 9.53 LEP
5 Increased shRNA abundance (Z-score > 2) GR00366-A-113 9.53 LEP
6 Increased shRNA abundance (Z-score > 2) GR00366-A-127 9.53 LEP XBP1
7 Increased shRNA abundance (Z-score > 2) GR00366-A-137 9.53 XBP1
8 Increased shRNA abundance (Z-score > 2) GR00366-A-138 9.53 XBP1
9 Increased shRNA abundance (Z-score > 2) GR00366-A-199 9.53 LEP
10 Increased shRNA abundance (Z-score > 2) GR00366-A-206 9.53 NR1H3
11 Increased shRNA abundance (Z-score > 2) GR00366-A-213 9.53 LEP
12 Increased shRNA abundance (Z-score > 2) GR00366-A-216 9.53 LEP
13 Increased shRNA abundance (Z-score > 2) GR00366-A-29 9.53 XBP1
14 Increased shRNA abundance (Z-score > 2) GR00366-A-38 9.53 NR1H3
15 Increased shRNA abundance (Z-score > 2) GR00366-A-55 9.53 LEP

MGI Mouse Phenotypes related to Fatty Liver Disease:

45 (show all 18)
# Description MGI Source Accession Score Top Affiliating Genes
1 homeostasis/metabolism MP:0005376 10.46 ADIPOQ CCL2 CYP2E1 IL6 INS IRS1
2 liver/biliary system MP:0005370 10.44 ADIPOQ CCL2 CYP2E1 IL6 INS IRS1
3 nervous system MP:0003631 10.35 ADIPOQ CCL2 IL6 INS IRS2 LEP
4 adipose tissue MP:0005375 10.34 ADIPOQ CCL2 IL6 INS IRS1 IRS2
5 growth/size/body region MP:0005378 10.34 ADIPOQ CCL2 CYP2E1 IL6 INS IRS1
6 muscle MP:0005369 10.33 ADIPOQ CCL2 IL6 INS IRS1 IRS2
7 cellular MP:0005384 10.31 ADIPOQ CCL2 IL6 INS IRS1 IRS2
8 cardiovascular system MP:0005385 10.28 ADIPOQ CCL2 CYP2E1 IL6 INS IRS1
9 neoplasm MP:0002006 10.27 ADIPOQ CCL2 CYP2E1 IL6 LEP LEPR
10 endocrine/exocrine gland MP:0005379 10.22 ADIPOQ IL6 INS IRS1 IRS2 LEP
11 immune system MP:0005387 10.2 ADIPOQ CCL2 IL6 INS IRS1 IRS2
12 behavior/neurological MP:0005386 10.18 ADIPOQ CCL2 CYP2E1 IL6 INS IRS2
13 renal/urinary system MP:0005367 10.16 ADIPOQ IL6 INS IRS2 LEP LEPR
14 digestive/alimentary MP:0005381 10.06 CCL2 IL6 INS LEP LEPR NR1H4
15 skeleton MP:0005390 10 ADIPOQ CCL2 CYP2E1 IL6 INS IRS1
16 mortality/aging MP:0010768 9.86 ADIPOQ CCL2 CYP2E1 IL6 INS IRS1
17 vision/eye MP:0005391 9.85 CCL2 IL6 INS IRS1 IRS2 LEP
18 integument MP:0010771 9.36 ADIPOQ CCL2 IL6 INS IRS2 LEP

Drugs & Therapeutics for Fatty Liver Disease

Drugs for Fatty Liver Disease (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 431)
# Name Status Phase Clinical Trials Cas Number PubChem Id
Tocopherol Approved, Investigational Phase 4 1406-66-2
Losartan Approved Phase 4 114798-26-4 3961
Angiotensin II Approved, Investigational Phase 4 68521-88-0, 11128-99-7, 4474-91-3 172198
Milk thistle Approved, Experimental, Investigational Phase 4 65666-07-1
Simvastatin Approved Phase 4 79902-63-9 54454
Telmisartan Approved, Investigational Phase 4 144701-48-4 65999
Amlodipine Approved Phase 4 88150-42-9 2162
Perindopril Approved Phase 4 82834-16-0, 107133-36-8 107807
Midazolam Approved, Illicit Phase 4 59467-70-8 4192
Alogliptin Approved Phase 4 850649-61-5 11450633
Glucagon Approved Phase 4 16941-32-5 16133228 16186314
Liraglutide Approved Phase 4 204656-20-2 44147092 16134956
Gliclazide Approved Phase 4 21187-98-4 3475
Glimepiride Approved Phase 4 93479-97-1 3476
Ezetimibe Approved Phase 4 163222-33-1 150311
Ursodeoxycholic acid Approved, Investigational Phase 4 128-13-2 31401
Rifampicin Approved Phase 4 13292-46-1 135512673 5381226 135900090
Insulin aspart Approved Phase 4 116094-23-6 16132418
Insulin detemir Approved Phase 4 169148-63-4 16137271
Pentoxifylline Approved, Investigational Phase 4 6493-05-6 4740
Selenium Approved, Investigational, Vet_approved Phase 4 7783-07-5, 7782-49-2 533
Adenosine Approved, Investigational Phase 4 58-61-7 60961
Phentermine Approved, Illicit Phase 4 122-09-8 4771
Montelukast Approved Phase 4 158966-92-8 5281040
Orlistat Approved, Investigational Phase 4 96829-58-2 3034010
Efavirenz Approved, Investigational Phase 4 154598-52-4 64139
Benzocaine Approved, Investigational Phase 4 1994-09-7, 94-09-7 2337
Tannic acid Approved Phase 4 1401-55-4 16129878 16129778
Sorbitol Approved, Investigational Phase 4 69-65-8, 50-70-4 453 6251 5780
Dapagliflozin Approved Phase 4 461432-26-8 9887712
Estradiol Approved, Investigational, Vet_approved Phase 4 50-28-2 5757
Polyestradiol phosphate Approved Phase 4 28014-46-2
Methyltestosterone Approved Phase 4 58-18-4 6010
Testosterone undecanoate Approved, Investigational Phase 4 5949-44-0 21873174 65157
Testosterone enanthate Approved Phase 4 315-37-7 9416
Testosterone Approved, Investigational Phase 4 58-22-0 5408 6013
Cetrorelix Approved, Investigational Phase 4 120287-85-6 25074887
Empagliflozin Approved Phase 4 864070-44-0 73151030 11949646
Dulaglutide Approved, Investigational Phase 4 923950-08-7
Ketotifen Approved Phase 4 34580-14-8, 34580-13-7 3827
Histamine Approved, Investigational Phase 4 51-45-6 774
Alendronic acid Approved Phase 4 121268-17-5, 66376-36-1 2088
Calcium carbonate Approved, Investigational Phase 4 471-34-1
Denosumab Approved Phase 4 615258-40-7
Metformin Approved Phase 4 1115-70-4, 657-24-9 4091
Pioglitazone Approved, Investigational Phase 4 111025-46-8 4829
Insulin glargine Approved Phase 4 160337-95-1 118984454
Rosiglitazone Approved, Investigational Phase 4 122320-73-4, 155141-29-0 77999
Zinc cation Approved, Experimental, Investigational Phase 4 7440-66-6, 23713-49-7 32051
Rifaximin Approved, Investigational Phase 4 80621-81-4 46783403 6436173

Interventional clinical trials:

(show top 50) (show all 1306)
# Name Status NCT ID Phase Drugs
1 THE EFFECT OF DUAL TREATMENT WITH L-CARNITINE AND MAGNESIUM ON Patients With Non Alcoholic Fatty Liver Disease Unknown status NCT01956825 Phase 4
2 Placebo Controlled Study Using Lovaza as Treatment for Non-Alcoholic Fatty Liver Disease Unknown status NCT00941642 Phase 4 Lovaza;placebo control
3 Comparison of The Effects of Thiazolidinediones(TZD), Sodium- Glucose Cotransporter 2 Inhibitors(SGLT2i) Alone and TZD / SGLT2i Combination Therapy on Non-alcoholic Fatty Liver Disease in Type 2 Diabetic Patients With Fatty Liver Unknown status NCT03646292 Phase 4 Pioglitazone;Empagliflozin;Combination of pioglitazone and empagliflozin
4 Evaluation of Perindopril and Telmisartan for the Treatment of Nonalcoholic Fatty Liver Disease: A Randomized Controlled Trial Unknown status NCT02213224 Phase 4 Perindopril;Telmisartan;Amlodipine
5 Effect of Metadoxine on Oxidative Stress in Non-alcoholic Fatty Liver Disease Prediabetic Mexican Patients Unknown status NCT02051842 Phase 4 Metadoxine
6 S.P.PRO LIVER POWDER is Used to Improve Liver and Metabolic Indexes in People With Non-alcoholic Fatty Liver Disease Unknown status NCT04718051 Phase 4 Shen Pu Yang Gan Wan;Placebo
7 The Effect of Consecutive Fecal Microbiota Transplantation on Non-Alcoholic Fatty Liver Disease (NAFLD) - a Randomized-controlled Trial - Unknown status NCT04465032 Phase 4
8 An Randomized Open Label Trial on the Impact of 24 Weeks of Atorvastatin Therapy on Liver Fat Content and Abdominal Fat Content in Patients With Type 2 Diabetes Combined With High LDL-C and Non-alcoholic Fatty Liver Disease Unknown status NCT01720719 Phase 4 atorvastatin;Vitamin E
9 The Effect of Empagliflozin on NAFLD in Asian Patients With Type 2 Diabetes Unknown status NCT02964715 Phase 4 Empagliflozin
10 A Randomised Controlled Trial of Lifestyle Versus Ezetimibe Plus Lifestyle in Patients With Non-alcoholic Steatohepatitis Unknown status NCT01950884 Phase 4 Ezetimibe
11 Pilot Study to Assess the Antiviral Activity and Safety of Besifovir Dipivoxil 150mg and L-carnitine 660mg Compared to Tenofovir Alafenamide 25mg in Chronic Hepatitis B Patients With Nonalcoholic Fatty Liver Unknown status NCT03604016 Phase 4 Besifovir dipivoxil;L-carnitine;Tenofovir Alafenamide
12 Efficacy and Safety of Berberine in Non-alcoholic Steatohepatitis: a Multicentre, Randomised, Placebo-controlled Trial Unknown status NCT03198572 Phase 4 Placebo;Berberine
13 To Evaluate the Effect of Nesinaact on Non-alcoholic Steatohepatitis Through MRI and Liver Fibroscan in Patients With Type 2 Diabetes: A Prospective, Open-Label, Single-Arm, Single-Center Clinical Study Unknown status NCT03950505 Phase 4 Nesinaact 25/15 (Alogliptin benzoate 25mg, pioglitazone hydrochloride 15mg) treatment for 24 weeks
14 Randomized Study Comparing Switching to Raltegravir-based Antiretroviral Versus Maintaining Any Other Antiretroviral Therapy in HIV Monoinfected Patients Impact on Fatty Liver and Liver Fibrosis Assessed by Noninvasive Diagnostic Methods Unknown status NCT02210715 Phase 4 Isentress.
15 Complex Imaging Assessment of Steatosis in Patients Under Treatment With Combination Silimarin, Phyllanthus Niruri and Choline Unknown status NCT02669641 Phase 4
16 Effect of Liraglutide on Fatty Liver Content Evaluated by Proton-spectroscopy (1H-spectroscopy) and Lipoprotein Kinetic, in Patients With Type 2 Diabetes Unknown status NCT02721888 Phase 4 Liraglutide;MRI/ MRS (Magnetic Resonance Imaging /Magnetic Resonance Spectroscopy)
17 Ultrasonographic Modification of Liver Steatosis and Visceral Fat Induced by Treatment With Losartan and Simvastatin in Hypertensive Normocholesterolemic Obese Patients Unknown status NCT00669435 Phase 4 Losartan + Simvastatin;Amlodipine + Simvastatin
18 Influence of Hepatic Steatosis on the Therapeutic Effect of Entecavir in Chronic Hepatitis B Patients-A Randomized, Double-Blinded, Controlled Trial Unknown status NCT01148576 Phase 4 entecavir;essentiale + entecavir;Vitamin E + entecavir
19 Efficacy of Liraglutide vs. Sitagliptin vs. Insulin Glargine Per Day on Liver Fat When Combined With Metformin in T2DM Subjects With Non-alcoholic Fatty-liver Disease Completed NCT02147925 Phase 4 Liraglutide combined with metformin;Insulin glargine combined with metformin;Sitagliptin combined with metformin
20 Comparison of Efficacy of Liraglutide, Metformin and Gliclazide MR on Hepatic Lipid Content in Patients With Type 2 Diabetes (T2DM) and Non-alcoholic Fatty Liver (NAFLD) Completed NCT03068065 Phase 4 Liraglutide;Metformin;Gliclazide
21 Efficacy of Pioglitazone Hydrochloride and Metformin Hydrochloride Tablets on the Patients With Newly Diagnosed Type 2 Diabetes Mellitus Combined With Non-alcoholic Fatty Liver Disease:an Multicenter,Randomized, Double-blind, Parallel- Controlled Study. Completed NCT03796975 Phase 4 Combination of Pioglitazone and Metformin Tablets;Metformin Hydrochloride Tablets
22 Pleiotropic Effects and Safety of Sodium Glucose Co-transporter 2 Inhibitor Versus Sulfonylurea in Patients With Type 2 Diabetes and Non-alcoholic Fatty Liver Completed NCT02649465 Phase 4 Tofogliflozin;Glimepiride
23 Effects of Empagliflozin on Liver Fat Content, Energy Metabolism and Body Composition in Patients With Type 2 Diabetes Completed NCT02637973 Phase 4 Empagliflozin;Placebo
24 A Multicenter, Double-blind, Active-controlled, Randomized, Parallel, Phase IV Clinical Trial to Evaluate the Efficacy and Safety of Evogliptin in Patients With Type 2 Diabetes and Non-alcoholic Fatty Liver Diseases Completed NCT03910361 Phase 4 Evogliptin;Pioglitazone
25 A 24 Week, Multicenter, Prospective, Open-labeled, Single-arm, Exploratory Phase 4 Clinical Trial to Evaluate the Safety and Efficacy of Lobeglitazone in Decreasing Intrahepatic Fat Contents in Type 2 Diabetes With NAFLD Completed NCT02285205 Phase 4 Oral administration of Lobeglitazone
26 The Effects of Purified n-3 Fatty Acids on Serum Fibrosis Markers and Cardiovascular Risk Markers in a Randomized Placebo Controlled Trial in Patients With Non Alcoholic Fatty Liver Disease Completed NCT00760513 Phase 4 OMACOR;Placebo oral capsule
27 Exenatide BID Compared With Insulin Glargine to Change Liver Fat Content in Non-alcoholic Fatty-liver Disease Patients With Type 2 Diabetes Completed NCT02303730 Phase 4 Exenatide;insulin glargine
28 PXR-aktivaation Vaikutus Maksan Rasvoittumiseen Completed NCT02329405 Phase 4 Rifampicin;Placebo
29 A New Treatment Strategy of Adding Exenatide to Insulin Therapy for Patients With Type 2 Diabetes and Non-Alcoholic Fatty Liver Disease (NAFLD) Completed NCT01006889 Phase 4 Exenatide
30 Use of Vitamin D in Treatment of Non-Alcoholic Fatty Liver Disease Detected by Transient Elastography Completed NCT04038853 Phase 4 1,25-Dihydroxyvitamin D;Placebo
31 Long-term Role of Pioglitazone in Non-Alcoholic Fatty Liver Disease (NAFLD) in Type 2 Diabetes Mellitus (T2DM). Completed NCT00994682 Phase 4 Pioglitazone study drug;Placebo;Pioglitazone Open Label
32 A Randomized, Prospective, Open Label, Active Control, Phase IV Study to Evaluate the Effects of Statin Monotherapy or Statin / Ezetimibe Combination Therapy on Hepatic Steatosis in Patients With Hyperlipidemia and Nonalcoholic Fatty Liver Disease Completed NCT03434613 Phase 4 Rosuvastatin;Rosuvastatin/ezetimibe combination
33 Effects of Exenatide (Byetta®) on Biochemical and Histological Parameters of Liver Function in Patients With Nonalcoholic Steatohepatitis (NASH) Completed NCT01208649 Phase 4 Exenatide
34 Impact of Short-term Fructose-enriched Diet on Serum Metabolome by Normal- and Over-weighed Women. Completed NCT03444233 Phase 4
35 The Effect of Vitamin D Supplementation on the Glycemic Control and Non-alcoholic Fatty Liver Disease in Type 2 Diabetes Completed NCT01854463 Phase 4 Vitamin D3;placebo
36 The Comparison of Effect Between Salsalate and Placebo in Osteoarthritis With Nonalcoholic Fatty Liver Disease: Investigator Initiated Randomized Placebo-controlled Double-blind, Pilot Study Completed NCT03222206 Phase 4 Salsalate
37 Effects of Ipragliflozin on Excessive Fat in Type 2 Diabetes Patients With Non-alcoholic Fatty Liver Disease Treated With Metformin and Pioglitazone Completed NCT02875821 Phase 4 Ipragliflozin;metformin with pioglitazone
38 A Randomized Study to Compare the Efficacy of Vitamin E, Ursodeoxycholic Acid and Pentoxyfylline on Egyptian Patients With Non-alcoholic Fatty Liver Disease Using (IL6 and CCL2) as a Predictors of Non-alcoholic Steatohepatitis Completed NCT04977661 Phase 4 Vitamin E;Ursodeoxycholic acid;Pentoxifylline
39 Effectiveness and Tolerability of Phentermine in the Reduction of Intrahepatic Fat Infiltration, Adipose Tissue and Postoperative Complications in Patients Under Bariatric Surgery Completed NCT03849729 Phase 4 Phentermine
40 Orlistat (Xenical) in the Treatment of Overweight Patients With Nonalcoholic Steatohepatitis (NASH) Completed NCT00160407 Phase 4 Orlistat (Xenical)
41 NAFLD in T2DM: Prevalence in Hispanics and Role of Treatment Completed NCT01002547 Phase 4 pioglitazone-placebo;pioglitazone;Vitamin E-placebo
42 Role of Pioglitazone in the Treatment of Non-alcoholic Steatohepatitis (NASH) Completed NCT00227110 Phase 4 Pioglitazone;Placebo
43 Clinical Study Evaluating the Efficacy and Safety of Montelukast in the Treatment of Non-Alcoholic Steatohepatitis (NASH) Completed NCT04537780 Phase 4 Montelukast
44 Magnetic Resonance Assessment of Victoza Efficacy in the Regression of Cardiovascular Dysfunction In Type 2 Diabetes Mellitus and South Asian Descent Completed NCT02660047 Phase 4 Liraglutide;Liraglutide - Placebo
45 MRI Substudy; Metabolic Changes Due to Iatrogenic Hypogonadism in Patients With Prostate Cancer: Orchiectomy vs. Triptorelin Completed NCT02102646 Phase 4 Triptorelin
46 Effect on Liver Fat, Adipose Tissue and Metabolic Parameters When Switching a Protease Inhibitor or Efavirenz to Once Daily Raltegravir in HIV+ Patients With Body Mass Index Over 25 kg/m2 and With at Least One Metabolic Syndrome Component Completed NCT03374358 Phase 4 Raltegravir
47 A Multi-Centered, Prospective, Randomized, Placebo-Controlled Clinical Trial for the Treatment of Significant Steatosis or NASH With Xenical Followed by Treatment of Hepatitis C (HCV) With PEG-Interferon Alpha-2a/Copegus Completed NCT00207311 Phase 4 Xenical, Pegasys, Copegus
48 Magnetic Resonance Assessment of Victoza Efficacy in the Regression of Cardiovascular Dysfunction In Type 2 Diabetes Mellitus Completed NCT01761318 Phase 4 Liraglutide;Liraglutide - Placebo
49 Evaluating the Effect of Pentoxifylline, Ursodiol, and Empagliflozin on Fatty Liver of Patients With Type-2 Diabetes Completed NCT04910178 Phase 4 Empagliflozin 25 MG;Ursodeoxycholic acid;Pentoxifylline 400 MG
50 Biochemical and Echosonographic Impacts Using Siliphos-Selenium-Methionine-Alpha Lipoic Acid + Metformin Versus Metformin in Patients With Fatty Liver and Steatohepatitis Completed NCT01650181 Phase 4 Metformin

Search NIH Clinical Center for Fatty Liver Disease

Cochrane evidence based reviews: fatty liver

Genetic Tests for Fatty Liver Disease

Anatomical Context for Fatty Liver Disease

Organs/tissues related to Fatty Liver Disease:

MalaCards : Liver, Skeletal Muscle, Kidney, Skin, Ovary, Endothelial, Heart

Publications for Fatty Liver Disease

Articles related to Fatty Liver Disease:

(show top 50) (show all 30413)
# Title Authors PMID Year
The Synergic Effect of a Nutraceutical Supplementation Associated to a Mediterranean Hypocaloric Diet in a Population of Overweight/Obese Adults with NAFLD. 62 41
36432436 2022
Change lifestyle modification plan/transtheoretical model in non-alcoholic simple fatty liver disease: a pilot randomized study. 62 41
36424552 2022
Predicting Factors for Metabolic Non-Response to a Complex Lifestyle Intervention-A Replication Analysis to a Randomized-Controlled Trial. 62 41
36432409 2022
Adiponectin: a key adipokine in alcoholic fatty liver. 53 62
19491377 2009
The multi-hit process and the antagonistic roles of tumor necrosis factor-alpha and adiponectin in non alcoholic fatty liver disease. 53 62
19561788 2009
Molecular mechanisms of alcoholic fatty liver. 53 62
19032584 2009
Adiponectin and alcoholic fatty liver disease. 53 62
18709650 2008
Role of adiponectin in the protective action of dietary saturated fat against alcoholic fatty liver in mice. 53 62
16108051 2005
Adiponectin and alcoholic fatty liver: Is it, after all, about what you eat? 53 62
16116627 2005
Role of fatty liver, dietary fatty acid supplements, and obesity in the progression of alcoholic liver disease: introduction and summary of the symposium. 53 62
15670659 2004
Clinical features and risk factors of patients with fatty liver in Guangzhou area. 53 62
15040041 2004
Relationship between genetic polymorphism of cytochrome P450IIE1 and fatty liver. 53 62
14606109 2003
Adverse Effect of Nonalcoholic Fatty Liver Disease on the Therapeutic Response in Patients with Chronic Hepatitis B. 62
36406311 2023
The Gut Microbiome and Ferroptosis in MAFLD. 62
36406312 2023
Triclocarban and triclosan exacerbate high-fat diet-induced hepatic lipid accumulation at environmental related levels: The potential roles of estrogen-related receptors pathways. 62
36372182 2023
USP10 Alleviates Palmitic Acid-induced Steatosis through Autophagy in HepG2 Cells. 62
36406315 2023
Prognostic Relevance of Metabolic Dysfunction-associated Steatohepatitis for Patients with Chronic Hepatitis B. 62
36406326 2023
A turn-on fluorescent probe based on ESIPT and AIEE mechanisms for the detection of butyrylcholinesterase activity in living cells and in non-alcoholic fatty liver of zebrafish. 62
36327810 2023
Gellan gum prevents non-alcoholic fatty liver disease by modulating the gut microbiota and metabolites. 62
36067688 2023
Effects of time-restricted feeding (16/8) combined with a low-sugar diet on the management of non-alcoholic fatty liver disease: A randomized controlled trial. 62
36257081 2023
Incidence and Impact of Non-alcoholic Fatty Liver Disease (NAFLD) in Patients with Adenocarcinoma of the Esophagus Treated with Curative Intent. 62
36264338 2023
Structural optimization and biological evaluation of 1-adamantylcarbonyl-4-phenylpiperazine derivatives as FXR agonists for NAFLD. 62
36375336 2023
Offspring NAFLD liver phospholipid profiles are differentially programmed by maternal high-fat diet and maternal one carbon supplement. 62
36270572 2023
Prognostic Value of Nonalcoholic Fatty Liver Disease in Patients With Severe Aortic Stenosis Who Underwent Transcatheter Aortic Valve Implantation. 62
36319504 2023
Exploring the active compounds and potential mechanism of the anti-nonalcoholic fatty liver disease activity of the fraction from Schisandra chinensis fruit extract based on multi-technology integrated network pharmacology. 62
36183952 2023
Uncovering the effect and mechanism of Panax notoginseng saponins on metabolic syndrome by network pharmacology strategy. 62
36058479 2023
Inhibition on XBP1s-driven lipogenesis by Qushi Huayu Decoction contributes to amelioration of hepatic steatosis induced by fructose. 62
36216198 2023
Different Types of Dietary Fat and Fructose Interactions Result in Distinct Metabolic Phenotypes in Male Mice. 62
36272691 2023
Hepatic DKK1-driven steatosis is CD36 dependent. 62
36410795 2023
Hepatic PGC-1α has minor regulatory effect on the liver transcriptome and metabolome during high fat high fructose diet and exercise training. 62
36368573 2023
One-step metal affinity purification of recombinant hFGF19 without using tags. 62
36206960 2023
Isolation of the Hepatic Ubiquitome/NEDDylome by Streptavidin Pull-Down Assay in the Biotinylated Ubiquitin (bioUb)/Biotinylated NEDD8 (bioNEDD8) Transgenic Mice. 62
36446973 2023
A method for quantifying hepatic and intestinal ceramides on mice by UPLC-MS/MS. 62
36375519 2023
The metabolic, protective, and immune functions of Akkermansia muciniphila. 62
36347103 2023
Side effect profile of pharmacologic therapies for liver fibrosis in nonalcoholic fatty liver disease: a systematic review and network meta-analysis. 62
36468565 2023
Pharmacotherapeutic efficacy on noninvasive fibrosis progression in nonalcoholic fatty liver disease: a systematic review and network meta-analysis. 62
36468574 2023
Elevated serum levels of diamine oxidase, D-lactate and lipopolysaccharides are associated with metabolic-associated fatty liver disease. 62
36468573 2023
Depletion of stearoyl-CoA desaturase (scd) leads to fatty liver disease and defective mating behavior in zebrafish. 62
36317480 2023
Genome Editing and Fatty Liver. 62
36454468 2023
Association of serum uric acid with all-cause and cardiovascular mortality among adults with nonalcoholic fatty liver disease. 62
35968564 2023
Regulatory effects mediated by ulvan oligosaccharide and its zinc complex on lipid metabolism in high-fat diet-fed mice. 62
36372481 2023
Serum sex hormone-binding globulin is a mediator of the association between intrahepatic lipid content and type 2 diabetes: the Maastricht Study. 62
36114428 2023
A diet-independent zebrafish model for NAFLD recapitulates patient lipid profiles and offers a system for small molecule screening. 62
36202338 2023
Ancestral BPA exposure caused defects in the liver of medaka for four generations. 62
36174697 2023
Physical activity is inversely associated with hepatic fibro-inflammation: A population-based cohort study using UK Biobank data. 62
36440257 2023
Comparison between obese and non-obese NAFLD. 62
36472052 2022
Adlay (Coix lacryma-jobi L.) Polyphenol Improves Hepatic Glucose and Lipid Homeostasis through Regulating Intestinal Flora via AMPK Pathway. 62
36214059 2022
Identification of high-risk subjects in NAFLD. 62
36472050 2022
Sex-specific associations of the urinary fourteen-metal mixture with NAFLD and liver fibrosis among US adults: A nationally representative study. 62
36402077 2022
Is elevated ALT associated with lifestyle risk factors? A population-based survey. 62
36404851 2022

Variations for Fatty Liver Disease

Expression for Fatty Liver Disease

Search GEO for disease gene expression data for Fatty Liver Disease.

Pathways for Fatty Liver Disease

Pathways related to Fatty Liver Disease according to GeneCards Suite gene sharing:

(show all 39)
# Super pathways Score Top Affiliating Genes
1 13.75 CCL2 IL6 INS IRS1 IRS2 LEP
Show member pathways
Show member pathways
Show member pathways
Show member pathways
Show member pathways
Show member pathways
Show member pathways
Show member pathways
11 11.98 TNF LEP IL6 CCL2
13 11.84 MAP3K5 IRS2 IRS1 IL6
Show member pathways
15 11.72 TNF IL6 CCL2
16 11.7 XBP1 TNF IL6
17 11.64 TNF IL6 CCL2
18 11.54 CCL2 IL6 TNF
19 11.54 LEPR LEP IRS2 IRS1
21 11.49 TNF IL6 CCL2
Show member pathways
11.45 SREBF1 NR1H3 INS
24 11.45 TNF IL6 CCL2
25 11.42 LEPR LEP IRS1 INS
26 11.28 TNF IL6 CCL2
27 11.25 PPARA NR1H4 NR1H3 CYP2E1
28 11.23 TNF IL6 CCL2
29 11.23 IRS2 IRS1 INS
30 11.11 TNF IRS1 ADIPOQ
Show member pathways
32 11.05 SREBF1 IRS2 IRS1
33 11.04 LEPR LEP INS
34 11.01 TNF IRS2 IRS1 INS
36 10.94 SREBF1 PPARA NR1H3
37 10.87 TNF SREBF1 NR1H4
38 10.68 IL6 CCL2
Show member pathways
10.35 TNF IL6

GO Terms for Fatty Liver Disease

Biological processes related to Fatty Liver Disease according to GeneCards Suite gene sharing:

(show all 36)
# Name GO ID Score Top Affiliating Genes
1 lipid metabolic process GO:0006629 10.27 XBP1 SREBF1 PNPLA3 NR1H3 LEP CYP2E1
2 negative regulation of inflammatory response GO:0050728 10.24 PPARA NR1H4 NR1H3 ADIPOQ
3 positive regulation of MAPK cascade GO:0043410 10.24 IL6 INS LEP MAP3K5 TNF
4 positive regulation of interleukin-6 production GO:0032755 10.21 XBP1 TNF LEP IL6
5 circadian rhythm GO:0007623 10.2 TNF SREBF1 LEP ADIPOQ
6 response to bacterium GO:0009617 10.19 TNF CYP2E1 CCL2 ADIPOQ
7 positive regulation of protein kinase B signaling GO:0051897 10.18 XBP1 TNF LEP INS
8 insulin receptor signaling pathway GO:0008286 10.18 SREBF1 IRS2 IRS1 INS
9 positive regulation of protein phosphorylation GO:0001934 10.18 ADIPOQ LEP LEPR MAP3K5 TNF XBP1
10 positive regulation of interleukin-8 production GO:0032757 10.17 TNF LEP IL6 ADIPOQ
11 cellular response to lipopolysaccharide GO:0071222 10.11 CCL2 IL6 NR1H3 NR1H4 TNF XBP1
12 positive regulation of receptor signaling pathway via JAK-STAT GO:0046427 10.1 TNF LEP IL6
13 response to activity GO:0014823 10.1 TNF LEP IL6 ADIPOQ
14 cellular response to fatty acid GO:0071398 10.08 SREBF1 NR1H4 IRS1
15 positive regulation of vascular associated smooth muscle cell proliferation GO:1904707 10.06 XBP1 TNF MAP3K5
16 negative regulation of gluconeogenesis GO:0045721 10.06 LEPR INS ADIPOQ
17 regulation of insulin secretion GO:0050796 10.05 TNF SREBF1 LEP IL6
18 fatty acid homeostasis GO:0055089 10.03 XBP1 NR1H4 INS
19 intracellular receptor signaling pathway GO:0030522 10.03 SREBF1 PPARA NR1H4 NR1H3
20 positive regulation of glycogen biosynthetic process GO:0045725 10.02 INS IRS1 IRS2
21 negative regulation of macrophage derived foam cell differentiation GO:0010745 10.01 PPARA NR1H3 ADIPOQ
22 positive regulation of glucose import GO:0046326 10.01 IRS2 IRS1 INS ADIPOQ
23 positive regulation of fatty acid beta-oxidation GO:0032000 10 PPARA IRS2 IRS1
24 response to sucrose GO:0009744 9.96 PNPLA3 ADIPOQ
25 regulation of bone remodeling GO:0046850 9.96 LEPR LEP
26 glucose metabolic process GO:0006006 9.96 TNF LEP IRS2 INS ADIPOQ
27 positive regulation of fatty acid metabolic process GO:0045923 9.95 ADIPOQ PPARA
28 bone growth GO:0098868 9.94 LEP LEPR
29 negative regulation of lipid storage GO:0010888 9.93 TNF LEP IL6
30 response to ethanol GO:0045471 9.93 ADIPOQ CYP2E1 LEP PPARA SREBF1 TNF
31 sterol homeostasis GO:0055092 9.92 XBP1 NR1H3
32 lipid localization GO:0010876 9.92 PPARA SREBF1
33 positive regulation of insulin receptor signaling pathway GO:0046628 9.92 NR1H4 LEP IRS1 INS
34 regulation of lipid storage GO:0010883 9.84 SREBF1 PPARA
35 glucose homeostasis GO:0042593 9.77 NR1H4 LEPR LEP IRS1 INS IL6
36 cellular response to insulin stimulus GO:0032869 9.44 XBP1 SREBF1 PNPLA3 LEP IRS2 IRS1

Molecular functions related to Fatty Liver Disease according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 sterol response element binding GO:0032810 9.46 SREBF1 NR1H3
2 insulin receptor binding GO:0005158 9.43 IRS2 IRS1 INS
3 nuclear receptor activity GO:0004879 9.23 SREBF1 PPARA NR1H4 NR1H3

Sources for Fatty Liver Disease

8 Cosmic
9 dbSNP
10 DGIdb
16 EFO
17 ExPASy
18 FMA
27 GO
28 GTR
30 HPO
31 ICD10
32 ICD10 via Orphanet
33 ICD11
36 LifeMap
40 MedGen
43 MeSH
44 MESH via Orphanet
45 MGI
48 NCI
49 NCIt
53 Novoseek
55 ODiseA
56 OMIM via Orphanet
57 OMIM® (Updated 08-Dec-2022)
61 PubChem
62 PubMed
70 Tocris
72 UMLS via Orphanet
Loading form....